Apr 1 |
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|
Mar 20 |
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Cyclacel Pharmaceuticals GAAP EPS of -$6.23 misses by $0.34
|
Mar 19 |
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 7 |
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
Mar 6 |
Cyclacel Pharmaceuticals receives $2.9M R&D tax credit
|
Mar 6 |
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
|
Feb 20 |
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
|
Jan 30 |
Cyclacel Pharmaceuticals stock slumps on termination of chief medical officer
|